Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics

Resistance to anti-tumor therapeutics is an important clinical problem. Tumor-targeted therapies currently used in the clinic are derived from antibodies or small molecules that mitigate growth factor activity. These have improved therapeutic efficacy and safety compared to traditional treatment mod...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Control Release
Main Authors: Sims, Jessica D., Taguiam, Jan Michael, Alonso-Valenteen, Felix, Markman, Janet, Agadjanian, Hasmik, Chu, David, Lubow, Jay, Abrol, Ravinder, Srinivas, Dustin, Jain, Anjali, Han, Bingchen, Qu, Ying, Mirzadehgan, Parisa, Hwang, Jae-Youn, Rentsendorj, Altan, Chung, Alice, Lester, Jenny, Karlan, Beth Y., Gray, Harry B., Gross, Zeev, Giuliano, Armando, Cui, Xiaojiang, Medina-Kauwe, Lali K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5807213/
https://ncbi.nlm.nih.gov/pubmed/29288681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2017.12.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados